FDA actions, week of October 12, 2026: 2 approvals, 1 rule, 3 notices, 1 announcement
The FDA published 7 actions so far in the week of October 12 to 18, 2026: 2 approval announcements, 1 final rule in the Federal Register, 3 notices in the Federal Register and 1 press announcement.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the agency's own record, grouped by the type of record.
This page updates as the week's records arrive. The week ends on Sunday, October 18, 2026.
Approvals
- FDA approves expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive NMIBC. On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, adding high-grade papillary-only tumors to the prior indication for carcinoma in situ. The approval is based on efficacy data from Cohort A of QUILT-3.032, which showed a 62% complete response rate (95% CI: 51, 73). Source: FDA approval page, October 14, 2026.
- FDA approves Brytly, a nonprescription eye drop for eye redness. The FDA approved Brytly, apraclonidine ophthalmic solution 0.125%, for relief of eye redness due to minor irritations. The approval is the first nonprescription eye drop containing apraclonidine and is available to adults and children 12 years of age and older. Source: FDA approval page, October 16, 2026.
Final rules
- FDA final rule permits salt substitutes in standardized foods. The rule, effective December 14, 2026, amends FDA's standards of identity to permit the use of salt substitutes in standardized foods. The change is intended to reduce sodium content in these foods. Source: Federal Register rule, October 13, 2026.
Notices
- FDA finalizes guidance on post-approval manufacturing changes to biosimilars. FDA announced the availability of a final guidance titled "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers." The guidance supersedes the draft issued July 23 2024 and withdraws Q&A I.20 from the Q&A biosimilar development guidance. Source: Federal Register notice, October 13, 2026.
- FDA authorizes emergency use of four animal drugs for New World screwworm. The FDA issued four Emergency Use Authorizations for products requested by Elanco US Inc., Zoetis Inc., Bimeda Animal Health Ltd., and Sergeant's Pet Care Products LLC to prevent infestations caused by New World screwworm larvae in various animals. The authorizations follow a HHS determination on August 18, 2025 that circumstances justify emergency use. Source: Federal Register notice, October 15, 2026.
- FDA announces support for forward compatibility of eCTD 4.0. The FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research announced support for forward compatibility of Electronic Common Technical Document (eCTD) Version 4.0. This notice informs stakeholders that submissions based on eCTD 4.0 are supported for forward compatibility. Source: Federal Register notice, October 16, 2026.
Other announcements
- FDA launches Rare Disease Framework Initiative to gather public feedback. The FDA announced the Rare Disease Framework Initiative on October 14, 2026, aiming to create a fit-for-purpose framework for rare disease drug development. It will host an October 28 meeting at its White Oak campus to solicit feedback from patients, advocates, and industry. Source: FDA press announcement, October 14, 2026.
How this page is made
Code builds this page from the stream briefs linked above, grouped by the type of record. No model writes this page. Software wrote each brief from one primary record, and code checked every number and name in it against that record. The source link opens the record itself.